Adial Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-52.0M | $-2.0M | $-1.8M | $-2.0M | $-2.2M | $-2.2M | $-2.5M | $-6.5M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | $141 | — | — | $141 | — | — | $141 |
| Stock-Based Compensation | — | $147.9K | — | — | $236.7K | — | — | $226.0K |
| Net Cash from Operating Activities | $-6.4M | $-1.6M | $-1.8M | $-1.7M | $-1.6M | $-1.7M | $-2.1M | $-1.6M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | $150.0K | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $315.3K | — | — | $50.6K | — | — | $3.8M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | — | — | — |